Sonoma Historical Balance Sheet

SNOA Stock

USD 2.13 0.02 0.95%

Trend analysis of Sonoma Pharmaceuticals balance sheet accounts such as Common Stock Shares Outstanding of 1.1 M, Liabilities And Stockholders Equity of 15.3 M, Total Current Assets of 12.6 M or Other Assets of 1.8 M provides information on Sonoma Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Sonoma Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Sonoma Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Sonoma Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Sonoma Pharmaceuticals is a good buy for the upcoming year.

Sonoma Pharmaceuticals Inventory

1.7 Million

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.

About Sonoma Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Sonoma Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Sonoma Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Sonoma Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Sonoma currently owns. An asset can also be divided into two categories, current and non-current.

Sonoma Pharmaceuticals Balance Sheet Chart

At present, Sonoma Pharmaceuticals' Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Cash is expected to grow to about 5.3 M, whereas Total Assets are forecasted to decline to about 15.3 M.

Total Assets Cash And Short Term Investments Common Stock Shares Outstanding Total Current Assets Current Deferred Revenue

Add Fundamental

Total Assets

Total assets refers to the total amount of Sonoma Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Sonoma Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Sonoma Pharmaceuticals balance sheet. This account contains Sonoma Pharmaceuticals investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Sonoma Pharmaceuticals fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most accounts from Sonoma Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Sonoma Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.At present, Sonoma Pharmaceuticals' Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Cash is expected to grow to about 5.3 M, whereas Total Assets are forecasted to decline to about 15.3 M.

	2022	2024	2025 (projected)
Other Assets	1.5M	1.8M	1.8M
Total Current Assets	13.8M	14.4M	12.6M

Other Assets Total Current Assets

Sonoma Pharmaceuticals balance sheet Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Total Current Assets	Other Assets	Other Stockholder Equity	Total Liab	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Current Deferred Revenue	Retained Earnings	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Inventory	Other Current Assets	Property Plant And Equipment Gross	Short Term Debt
Total Assets		0.85	-0.7	0.7	0.7	0.22	0.88	0.34	0.67	0.24	-0.5	0.03	0.04	-0.35	-0.21	-0.59	0.15	0.4	0.56	0.26	-0.68	0.0	0.46	0.27	0.05	-0.53
Total Stockholder Equity	0.85		-0.86	0.79	0.79	0.19	0.75	0.29	0.35	-0.31	-0.69	0.3	-0.21	-0.04	-0.32	-0.26	0.21	0.36	0.64	0.1	-0.38	-0.44	0.34	-0.03	-0.15	-0.79
Net Debt	-0.7	-0.86		-0.97	-0.97	0.13	-0.71	-0.13	-0.14	0.31	0.45	-0.33	0.16	-0.04	0.06	0.02	-0.17	-0.14	-0.52	0.21	0.25	0.45	-0.08	0.19	0.29	0.57
Cash	0.7	0.79	-0.97		1.0	-0.13	0.75	0.13	0.17	-0.19	-0.28	0.26	-0.13	0.01	-0.04	-0.1	0.19	0.05	0.55	-0.19	-0.35	-0.31	0.04	-0.15	-0.28	-0.41
Cash And Short Term Investments	0.7	0.79	-0.97	1.0		-0.13	0.75	0.13	0.17	-0.19	-0.28	0.26	-0.13	0.01	-0.04	-0.1	0.19	0.05	0.55	-0.19	-0.35	-0.31	0.04	-0.15	-0.28	-0.41
Common Stock Shares Outstanding	0.22	0.19	0.13	-0.13	-0.13		0.32	0.5	0.47	0.04	-0.3	-0.2	-0.25	-0.19	-0.57	-0.52	0.12	-0.15	0.33	0.77	-0.3	0.14	0.53	0.29	0.42	-0.17
Total Current Assets	0.88	0.75	-0.71	0.75	0.75	0.32		0.51	0.73	0.21	-0.32	-0.19	-0.22	-0.34	-0.45	-0.66	0.28	-0.08	0.7	0.32	-0.67	0.11	0.61	0.36	0.12	-0.31
Other Assets	0.34	0.29	-0.13	0.13	0.13	0.5	0.51		0.33	0.1	-0.24	-0.57	-0.34	0.04	-0.57	-0.38	-0.05	-0.22	0.64	0.16	-0.02	0.38	0.72	0.65	0.71	0.05
Other Stockholder Equity	0.67	0.35	-0.14	0.17	0.17	0.47	0.73	0.33		0.56	-0.21	-0.37	-0.14	-0.74	-0.48	-0.93	0.16	-0.03	0.34	0.64	-0.86	0.38	0.73	0.53	0.23	-0.16
Total Liab	0.24	-0.31	0.31	-0.19	-0.19	0.04	0.21	0.1	0.56		0.38	-0.5	0.46	-0.54	0.21	-0.58	-0.12	0.06	-0.16	0.29	-0.51	0.81	0.19	0.56	0.38	0.5
Short Long Term Debt Total	-0.5	-0.69	0.45	-0.28	-0.28	-0.3	-0.32	-0.24	-0.21	0.38		-0.17	0.24	0.18	0.24	0.15	0.24	-0.44	-0.14	-0.02	0.13	0.38	-0.26	-0.13	-0.19	0.86
Other Current Liab	0.03	0.3	-0.33	0.26	0.26	-0.2	-0.19	-0.57	-0.37	-0.5	-0.17		0.34	0.27	0.41	0.49	0.18	0.42	0.02	-0.04	0.1	-0.85	-0.44	-0.88	-0.78	-0.46
Total Current Liabilities	0.04	-0.21	0.16	-0.13	-0.13	-0.25	-0.22	-0.34	-0.14	0.46	0.24	0.34		0.08	0.76	0.12	0.08	0.51	-0.29	0.05	0.0	0.04	-0.37	-0.17	-0.14	0.23
Property Plant And Equipment Net	-0.35	-0.04	-0.04	0.01	0.01	-0.19	-0.34	0.04	-0.74	-0.54	0.18	0.27	0.08		0.08	0.7	0.33	-0.01	0.14	-0.33	0.78	-0.39	-0.33	-0.34	-0.13	0.07
Current Deferred Revenue	-0.21	-0.32	0.06	-0.04	-0.04	-0.57	-0.45	-0.57	-0.48	0.21	0.24	0.41	0.76	0.08		0.5	-0.32	0.43	-0.56	-0.44	0.22	-0.05	-0.77	-0.4	-0.25	0.22
Retained Earnings	-0.59	-0.26	0.02	-0.1	-0.1	-0.52	-0.66	-0.38	-0.93	-0.58	0.15	0.49	0.12	0.7	0.5		-0.14	0.09	-0.31	-0.63	0.85	-0.51	-0.67	-0.64	-0.34	0.03
Accounts Payable	0.15	0.21	-0.17	0.19	0.19	0.12	0.28	-0.05	0.16	-0.12	0.24	0.18	0.08	0.33	-0.32	-0.14		-0.22	0.43	0.42	-0.1	-0.31	0.25	-0.19	-0.41	-0.01
Non Current Assets Total	0.4	0.36	-0.14	0.05	0.05	-0.15	-0.08	-0.22	-0.03	0.06	-0.44	0.42	0.51	-0.01	0.43	0.09	-0.22		-0.14	-0.09	-0.09	-0.23	-0.22	-0.12	-0.11	-0.52
Non Currrent Assets Other	0.56	0.64	-0.52	0.55	0.55	0.33	0.7	0.64	0.34	-0.16	-0.14	0.02	-0.29	0.14	-0.56	-0.31	0.43	-0.14		0.27	-0.25	-0.15	0.65	0.06	-0.06	-0.2
Net Receivables	0.26	0.1	0.21	-0.19	-0.19	0.77	0.32	0.16	0.64	0.29	-0.02	-0.04	0.05	-0.33	-0.44	-0.63	0.42	-0.09	0.27		-0.51	0.1	0.56	0.12	0.05	-0.04
Common Stock Total Equity	-0.68	-0.38	0.25	-0.35	-0.35	-0.3	-0.67	-0.02	-0.86	-0.51	0.13	0.1	0.0	0.78	0.22	0.85	-0.1	-0.09	-0.25	-0.51		-0.26	-0.38	-0.26	0.06	0.18
Non Current Liabilities Total	0.0	-0.44	0.45	-0.31	-0.31	0.14	0.11	0.38	0.38	0.81	0.38	-0.85	0.04	-0.39	-0.05	-0.51	-0.31	-0.23	-0.15	0.1	-0.26		0.23	0.79	0.69	0.62
Inventory	0.46	0.34	-0.08	0.04	0.04	0.53	0.61	0.72	0.73	0.19	-0.26	-0.44	-0.37	-0.33	-0.77	-0.67	0.25	-0.22	0.65	0.56	-0.38	0.23		0.54	0.35	-0.12
Other Current Assets	0.27	-0.03	0.19	-0.15	-0.15	0.29	0.36	0.65	0.53	0.56	-0.13	-0.88	-0.17	-0.34	-0.4	-0.64	-0.19	-0.12	0.06	0.12	-0.26	0.79	0.54		0.85	0.18
Property Plant And Equipment Gross	0.05	-0.15	0.29	-0.28	-0.28	0.42	0.12	0.71	0.23	0.38	-0.19	-0.78	-0.14	-0.13	-0.25	-0.34	-0.41	-0.11	-0.06	0.05	0.06	0.69	0.35	0.85		0.23
Short Term Debt	-0.53	-0.79	0.57	-0.41	-0.41	-0.17	-0.31	0.05	-0.16	0.5	0.86	-0.46	0.23	0.07	0.22	0.03	-0.01	-0.52	-0.2	-0.04	0.18	0.62	-0.12	0.18	0.23

Click cells to compare fundamentals

Sonoma Pharmaceuticals Account Relationship Matchups

Sonoma Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	15.0M	18.8M	16.2M	14.7M	17.0M	15.3M
Total Stockholder Equity	5.4M	8.7M	8.0M	6.1M	7.1M	8.7M
Net Debt	(1.5M)	(6.0M)	(3.0M)	(2.5M)	(2.3M)	(2.4M)
Cash	4.2M	7.4M	3.8M	3.1M	2.8M	5.3M
Cash And Short Term Investments	4.2M	7.4M	3.8M	3.1M	2.8M	5.3M
Common Stock Shares Outstanding	199.6K	265.3K	339.4K	909K	1.0M	1.1M
Liabilities And Stockholders Equity	15.0M	18.8M	16.2M	14.7M	17.0M	15.3M
Total Current Assets	13.0M	16.4M	13.8M	12.5M	14.4M	12.6M
Other Assets	850K	875K	1.5M	1.5M	1.8M	1.8M
Other Stockholder Equity	189.2M	197.4M	200.9M	203.2M	233.7M	148.5M
Total Liab	9.6M	10.1M	8.3M	8.6M	9.9M	6.9M
Short Long Term Debt Total	2.7M	1.4M	849K	608K	547.2K	519.8K
Other Current Liab	(2.6M)	(2.0M)	(2.5M)	(2.8M)	(2.5M)	(2.4M)
Total Current Liabilities	4.1M	5.8M	3.7M	3.7M	3.3M	3.7M
Property Plant And Equipment Net	1.1M	879K	906K	651K	585.9K	958.7K
Current Deferred Revenue	319K	1.3M	160K	478K	430.2K	673.3K
Retained Earnings	(179.3M)	(184.4M)	(189.5M)	(194.3M)	(174.9M)	(183.7M)
Accounts Payable	1.8M	1.6M	841K	607K	546.3K	519.0K
Non Current Assets Total	2.0M	2.4M	2.4M	2.2M	2.5M	2.9M
Non Currrent Assets Other	875K	707K	578K	396K	455.4K	584.7K
Net Receivables	2.8M	2.4M	2.6M	2.9M	3.3M	2.3M
Non Current Liabilities Total	5.5M	4.3M	4.5M	4.9M	5.6M	5.9M
Inventory	2.5M	2.7M	2.9M	2.7M	3.1M	1.7M
Other Current Assets	3.4M	4.0M	4.5M	3.8M	4.4M	4.6M
Property Plant And Equipment Gross	1.1M	2.6M	2.9M	3.0M	3.5M	3.7M
Accumulated Other Comprehensive Income	(4.6M)	(4.3M)	(3.4M)	(2.7M)	(2.5M)	(2.6M)
Short Term Debt	1.1M	1.1M	943K	719K	647.1K	781.0K
Property Plant Equipment	365K	1.1M	879K	906K	815.4K	906.4K
Other Liab	245K	3.7M	4.0M	4.4M	5.0M	5.3M
Net Tangible Assets	8.7M	5.4M	8.7M	8.0M	7.2M	9.0M
Short Long Term Debt	596K	808K	431K	323K	371.5K	366.2K
Capital Lease Obligations	769K	559K	418K	285K	327.8K	478.6K
Net Invested Capital	7.3M	9.5M	8.4M	6.5M	5.8M	7.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

When determining whether Sonoma Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonoma Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonoma Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonoma Pharmaceuticals Stock:

How To Invest In Sonoma

Details

Is Sonoma Stock a good investment?

Details

What is Sonoma Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.

You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonoma Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.25)

Revenue Per Share

13.579

Quarterly Revenue Growth

0.136

Return On Assets

(0.20)

Return On Equity

(0.65)

The market value of Sonoma Pharmaceuticals is measured differently than its book value, which is the value of Sonoma that is recorded on the company's balance sheet. Investors also form their own opinion of Sonoma Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Sonoma Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonoma Pharmaceuticals' market value can be influenced by many factors that don't directly affect Sonoma Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Sonoma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonoma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Sonoma Historical Balance Sheet

Sonoma Pharmaceuticals Inventory

1.7 Million

About Sonoma Balance Sheet Analysis

Sonoma Pharmaceuticals Balance Sheet Chart

Total Assets

Cash And Short Term Investments

Common Stock Shares Outstanding

Total Current Assets

Current Deferred Revenue

Sonoma Pharmaceuticals balance sheet Correlations

Sonoma Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Sonoma Pharmaceuticals balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.88	Total Assets
Short Term Debt	+ 0.86	Short Long Term Debt Total
Total Stockholder Equity	+ 0.85	Total Assets
Common Stock Total Equity	+ 0.85	Retained Earnings
Property Plant And Equipment Gross	+ 0.85	Other Current Assets

Cash And Short Term Investments	- 0.97	Net Debt
Cash	- 0.97	Net Debt
Retained Earnings	- 0.93	Other Stockholder Equity
Other Current Assets	- 0.88	Other Current Liab
Common Stock Total Equity	- 0.86	Other Stockholder Equity
Net Debt	- 0.86	Total Stockholder Equity